共 50 条
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
被引:288
|作者:
Shim, Joong Sup
[1
]
Liu, Jun O.
[2
]
机构:
[1] Univ Macau, Fac Hlth Sci, Taipa, Macau, Peoples R China
[2] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
来源:
关键词:
drug repositioning;
drug discovery;
cancer;
angiogenesis;
drug screening;
drug library;
PROTEASE INHIBITOR NELFINAVIR;
BREAST-CANCER CELLS;
PHASE-I TRIAL;
HUMAN-IMMUNODEFICIENCY-VIRUS;
RESISTANT PROSTATE-CANCER;
CARDIAC-GLYCOSIDES;
GROWTH ARREST;
TUMOR-GROWTH;
LUNG-CANCER;
ENDOTHELIAL-CELLS;
D O I:
10.7150/ijbs.9224
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Drug repositioning (also referred to as drug repurposing), the process of finding new uses of existing drugs, has been gaining popularity in recent years. The availability of several established clinical drug libraries and rapid advances in disease biology, genomics and bioinformatics has accelerated the pace of both activity-based and in silico drug repositioning. Drug repositioning has attracted particular attention from the communities engaged in anticancer drug discovery due to the combination of great demand for new anticancer drugs and the availability of a wide variety of cell- and target-based screening assays. With the successful clinical introduction of a number of non-cancer drugs for cancer treatment, drug repositioning now became a powerful alternative strategy to discover and develop novel anticancer drug candidates from the existing drug space. In this review, recent successful examples of drug repositioning for anticancer drug discovery from non-cancer drugs will be discussed.
引用
收藏
页码:654 / 663
页数:10
相关论文